Biosimilars: the future of prescribing biological medicines

Biological medicines are an important advancement in the pharmaceutical treatment of patients with inflammatory and immunological diseases and cancer. Changes are occurring rapidly in this field of treatment as biosimilars become increasingly common in clinical practice. These medicines are comparable in all essential aspects to the innovator biological medicines they are based on, including safety, efficacy and mode of action, but cost significantly less. This overview of the use of biosimilars is intended for all health practitioners in both primary and secondary care.

**KEY PRACTICE POINTS:**

- Biological medicines are complex molecules produced by living cells that target specific receptors or proteins involved in disease progression, e.g. rheumatoid arthritis, Crohn’s disease, multiple sclerosis and some cancers; biologicals are one of the fastest growing therapeutic classes.
- A biosimilar is a comparable version of a biological medicine (the innovator) that already has regulatory approval, i.e. the reference medicine.
- The development of biosimilars reduces the overall cost to the healthcare system of biological medicines, thereby facilitating greater patient access to treatment.
- The number of funded biosimilars in New Zealand will increase as the patents on reference medicines expire. In some cases, patients may need to be transitioned from a reference medicine to a biosimilar in order to continue to receive the funded treatment; effective communication and provision of suitable information is essential.
- From 1 March, 2020, a rituximab biosimilar (Riximyo; Novartis*) will replace the rituximab reference medicine (MabThera; Roche) as the funded treatment for many indications.

* Riximyo is supplied by Novartis under the Sandoz brand.
**Biological medicines and the advent of biosimilars**

The development of biological medicines over the past 20 years has improved the treatment of conditions involving inflammatory and immunological changes, such as rheumatoid arthritis, Crohn’s disease, multiple sclerosis and some cancers. These medicines are typically large, complex molecules produced by genetically engineered cells that target specific receptors or proteins involved in disease progression. Biological medicines include:

- Monoclonal antibodies* (mabs) that target a single epitope on an antigen, e.g. rituximab binds to CD20 proteins on the surface of antibody producing B cells
- Recombinant hormones†, cytokines and growth factors, e.g. insulin, erythropoietin and human growth hormone
- Fusion proteins‡, e.g. etanercept where the extracellular domain of tumour necrosis factor alpha (TNFα) is fused to part of a human IgG protein
- Antibody-drug conjugate, e.g. trastuzumab + emtansine where the antibody is bound to a small cytotoxic molecule to deliver the medicine to the target cells

* Created using a genetically identical population of immune cells
† Created by expressing cloned genetic material in a non-native host cell, e.g. human genes expressed within an animal cell line
‡ Created by joining two or more genes or portions of genes that originally encoded separate proteins

**Biosimilars closely resemble reference medicines but are not identical**

When a manufacturer produces an innovator (reference) biological medicine, it is typically given patent protection for ten years for the indications that the medicine has been approved for. Once this period has lapsed, other companies are able to market comparable medicines to compete with the innovator medicine, after they have gained regulatory approval. These medicines are referred to as biosimilars.

A biosimilar is comparable in all essential aspects to a biological medicine that has already been approved. Biosimilars have robust evidence demonstrating they are not associated with any clinically meaningful difference in terms of safety and efficacy, compared to the reference medicine (see: “Comparing the safety and efficacy of biosimilar and reference medicines”).

**Biological medicines are expensive**

The average cost of developing a biological medicine has been estimated at $2.9 billion dollars (NZD) and the global market for biologicals is predicted to be $600 billion (NZD) in 2020.2 The high overall cost of biological medicines to the health system is due to:

- The generally high price of patented biological medicines
- The increasing prevalence in ageing populations of conditions that biologicals are indicated for, e.g. cancer
- The increasing number of indications for which biological medicines are approved
- People needing to be treated for longer as life expectancy increases

**Biosimilars reduce the cost of treatment**

Currently, many biological medicines are not funded, or are only funded for limited indications, due to their high cost. These medicines are therefore only accessible to people who can afford to pay the cost of treatment. Biological medicines are likely to become more widely available as the patents for innovator biological medicines expire and competition increases, resulting in cost reductions. Prescribing biosimilars has reduced health spending on biological medicines by 20–40% in Europe and the United States. The cost of developing a biosimilar is, however, still high at $150–380 million (NZD) per medicine and typically takes seven to eight years.3

**The global uptake of biosimilars**

Europe has been progressive in approving the use of biosimilar medicines. The European Medicines Agency (EMA) had approved 62 biosimilars as of December, 2019.4 Approval of biosimilars has been less rapid in the United States, with 26 biosimilar medicines being approved as of the same date.5 In Australia, 25 biosimilars had been approved as of January, 2020, 14 of which are subsidised.6

European countries have also been proactive in encouraging the use of biosimilar medicines in clinical practice. A target has been set in the United Kingdom for 90% of patients newly diagnosed with a condition for which a biosimilar is indicated to be initiated on the best value biological medicine within three months.7 It is also expected that 80% of patients being treated for more than six months with a biological should be switched to the best value medicine within one year of that medicine being available.7 The uptake of biosimilars has been relatively rapid in many other European countries, including Denmark and France. For example, three to four months after the patents for the TNF inhibitors etanercept and infliximab expired in Denmark and following regulatory changes, the respective biosimilars accounted for 85–90% of the total prescribing of these biological medicines (see: “The NOR-SWITCH trial and the Danish experience: infliximab and etanercept biosimilars”).8
Biosimilars in New Zealand

There are three biosimilar medicines currently funded in New Zealand with Special Authority Approval:

- **Zarzio** (filgrastim biosimilar); recombinant human G-CSF indicated for neutropenias and for use with autologous infusions and bone marrow transplants
- **Omnitrope** (somatropin biosimilar); recombinant human growth hormone indicated for growth hormone deficiency, Prader-Willi syndrome and Turner syndrome
- **Binocrit** (epoetin alfa biosimilar); recombinant human erythropoietin indicated for anaemia associated with renal failure or chemotherapy

A rituximab biosimilar (Riximyo) will be funded from March 1, 2020 (see: “Rituximab: reference medicine MabThera and biosimilar Riximyo”).

There are a number of other biosimilar medicines that will be considered for funding by PHARMAC in the near future, e.g. a trastuzumab biosimilar. As prices reduce due to increased competition among suppliers, any biological medicine, whether a reference medicine or biosimilar, may become a newly funded brand, or have a newly funded indication, in New Zealand.

Comparing the safety and efficacy of biosimilar and reference medicines

In New Zealand, Medsafe applies the same regulatory standards for approving a biosimilar medicine as the European Medicines Agency (EMA). These guidelines require the manufacturer of a biosimilar product to demonstrate that the biosimilar:

A. **Is similar to the reference medicine in terms of chemical and physical properties.** This is assessed by a range of laboratory experiments, such as antigen binding tests for antibodies. In general, there is no “gold standard” to quantify chemical and physical similarity; the purpose of these tests is to identify any differences between the biosimilar and the original biologic.

   If the active component of a biological medicine is a protein, both the reference medicine and the biosimilar must contain the same amino acid sequence and the same three-dimensional structure (protein folding). The active component of the medicine must also be present in the same concentration and be delivered by the same route of administration.

B. **Does not have any meaningful differences from the reference medicine in terms of quality, safety or efficacy.** This is assessed by a variety of tests including pharmacodynamic and pharmacokinetic studies, as well as clinical trials of efficacy compared to the reference biological. These tests must demonstrate that any detected differences in chemical or physical properties do not have a meaningful impact on clinical efficacy and safety.

Microheterogeneity refers to the minor variability between reference medicines and biosimilars, e.g. small differences in glycosylation patterns (which determine protein structure, function and stability). This same degree of variability may also be present between batches of a biological medicine produced by the same company, especially if the manufacturing process is modified during the commercial life of the medicine.

Microheterogeneity occurs because biological medicines are large complex molecules produced by applying proprietary technology to living cells; they are therefore very difficult to characterise in a laboratory.

The EMA has additional specific criteria for assessing comparability depending on the type of biological medicine under consideration, the medicine’s mechanism of action and the safety and efficacy of the reference medicine.

Further information on Medsafe’s approval process for biosimilar medicines is available from: [www.medsafe.govt.nz/profs/RIss/Medsafe%20position%20on%20biosimilars.pdf](http://www.medsafe.govt.nz/profs/RIss/Medsafe%20position%20on%20biosimilars.pdf)


Adverse reactions and immunogenicity

Adverse reactions associated with biological medicines may be due to administration-site reactions (mild cutaneous or hypersensitivity reactions are common), pharmacological action or immunological reactions.

Immunogenicity is a significant safety concern with biological medicines

The ability of a biological medicine to provoke an immune response (immunogenicity) is an important safety concern. Immune responses to biological medicines are often limited and not severe, e.g. the transitory production of antibodies that may decrease treatment efficacy. However, more serious consequences are possible including infections, reactivation of disease, e.g. tuberculosis or cancer, and rarely systemic hypersensitivity reactions, e.g. cytokine release syndrome (cytokine storm).

As of 2019, there is no published study demonstrating that a biosimilar is associated with increased immunogenicity, compared to its relevant reference medicine.
Biosimilars and reference medicines have comparable safety profiles

The perceived concerns about biosimilars among clinicians and patients often stem from the observation that biosimilars are “similar but not identical” to reference medicines.14, 15 Reassurance is provided by a large and accumulating body of evidence supporting the safety and efficacy of biosimilars. A systematic review of 90 studies with more than 14,000 patients and seven different biosimilars used to treat 14 conditions found no statistically significant differences in the rate of adverse reactions associated with the use of reference medicines.16

At an individual medicine level, comparisons of safety and efficacy between reference medicines and biosimilars often involve switching studies, i.e. patients taking a reference medicine switching to a biosimilar (see: “The NOR-SWITCH trial and the Danish experience: infliximab and etanercept biosimilars”). A systematic review of 63 publications involving 57 switching studies reported comparable safety and efficacy profiles between reference medicines and biosimilars in virtually all cases, although many trials were relatively small without long-term follow-up.17 There were two exceptions involving treatment-related adverse effects. The PLANETAS extension study of 174 patients taking infliximab for the treatment of ankylosing spondylitis, reported adverse effects during the extension phase of the study in 22% of patients on maintenance treatment and 39% of patients who were switched to a biosimilar (CT-P13).18 Back pain and latent tuberculosis were the adverse effects reported as being more frequent in the extension phase following the switch to the biosimilar.18 The second exception involved 452 patients with type 1 diabetes, a subset of whom were switched to a biosimilar insulin glargine and subsequently experienced a small, but statistically significant increase in weight of +1 kg, compared to +0.2 kg for patients who remained on the innovator insulin; no other differences in safety or efficacy were identified.19

Once biosimilars enter the market, post-market surveillance occurs to detect unexpected responses in individuals, e.g. rare immune reactions, or groups that may have not been studied extensively in trials, e.g. children or complex patients with co-morbidities or polypharmacy (especially immunosuppressants).1

Extrapolation to other indications may be possible

The practice of extrapolating indications for biosimilars from reference medicines may also be a concern for some clinicians.14 Extrapolation refers to the assumption that if there are data showing that a biosimilar is safe and effective for one indication for which a reference medicine has approval, the biosimilar is also safe and effective for the other indications that the reference medicine is approved for. Extrapolation only occurs if there is a substantial body of evidence demonstrating that the biosimilar has comparable characteristics that are relevant for the specific indication1

This means that biosimilar medicines may not need the same number of clinical trials as reference medicines which must undergo clinical trial(s) for every indication they are approved for. The practice of extrapolation results in fewer clinical trials, thereby reducing the number of patients who need to be recruited and reducing the cost of medicine development.

Planning for the introduction of biosimilars

The following factors have been identified as being critical for the successful introduction of biosimilars into clinical practice:6, 23

- Good communication with (and between) patients and clinicians
- The provision of educational material for patients and clinicians
- Adequate time to implement changes and monitor patients for potential adverse effects
- Consistent reporting of any adverse effects

The entire healthcare team will be involved to some extent in the transition to biosimilars, e.g. prescriber discussing the new medicine with the patient and initiating treatment, pharmacist dispensing and recording information about the medicine (see: “Pharmacists should record the batch number…”) and nurse or other clinicians monitoring patient response. In a secondary care setting, it is recommended that each aspect of managing the introduction of a biosimilar be assigned to one person who can act as an implementation lead.

Some clinicians may require additional reassurance to prescribe with confidence

Due to the relatively low use of biosimilars in New Zealand, some prescribers may be unfamiliar with these medicines and require additional information in order to prescribe them confidently. A 2017 survey of 110 secondary care prescribers (rheumatologists, oncologists, dermatologists, gastroenterologists and haematologists) showed that a minority had concerns which included the practice of extrapolating indications, switching patients from reference medicines to biosimilars, potential adverse effects and the amount of time it would take to explain biosimilars to patients.24 Biosimilars are a rapidly changing area of medicine, however, and the accumulating evidence of safety and efficacy from European countries means that knowledge and confidence about biosimilars may have increased since this survey.
Transitioning patients from reference medicines to biosimilars
Clinically any two medicines are interchangeable if they can both be prescribed for the same indication, without any difference in clinical effect.\(^1,2\) With biological medicines, this generally applies to changing from a reference medicine to a biosimilar, but it is also possible to change from a biosimilar to a reference medicine or between two biosimilars. The process of interchanging medicines may occur in two ways:\(^1\)

1. Switching, where the prescriber exchanges one medicine for another with the same therapeutic intent
2. Substitution, where a pharmacist dispenses one medicine in preference to another without consulting the prescriber (e.g. generic substitution); this is not approved in New Zealand for biological medicines

Therefore, biological medicine brands can be switched with mutual agreement from the prescriber and patient, but brands may not be substituted at the pharmacy without prescriber agreement.\(^25\)

Reasons to change a biological medicine brand
Prescribers may decide with the patient to switch biological medicines:
- To improve treatment efficacy
- To improve tolerability
- Due to issues relating to an administration device
- To reduce the cost of treatment due to funding, availability or supply issues

Effective communication is critical
If a patient is transitioned from a reference medicine to a biosimilar, communication with the patient and informed consent needs to be carefully managed. If patients develop negative perceptions towards biosimilars they may become anxious or concerned about their treatment, which can in turn adversely affect outcomes.\(^15\) This is especially important for biosimilars that are self-administered, as non-adherence to treatment may become an issue.\(^23\) Maximising face-to-face contact with the patient during the education and consent process and providing written and online educational material reduces the likelihood that patients will seek information from unreliable sources.

Positively framing discussions about biosimilars, while still providing balanced information about risks and adverse effects, has been shown to increase patient willingness to switch from a reference medicine to a biosimilar, i.e. focusing on the similarities between the two medicines.\(^15\) A New Zealand study of 96 patients currently taking a biological medicine (35%...
Rituximab is a chimeric murine/human monoclonal antibody that destroys antibody producing B cells by targeting CD20 proteins on their cell surface.\textsuperscript{11} MabThera (Roche) is the reference brand of rituximab and is approved in New Zealand to treat autoimmune disorders and cancers including non-Hodgkin’s lymphoma, lymphocytic leukaemia, rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis.\textsuperscript{28} Three patents covering the treatment or prevention of B-cell lymphoma with MabThera expired in August, 2019, and four more patents relating to the treatment of non-malignant autoimmune disease and rheumatoid arthritis with MabThera are expiring between 2020 and 2026. Riximyo (Novartis*) is a rituximab biosimilar and is approved by Medsafe for the same indications as MabThera.\textsuperscript{29}

Access to rituximab will widen and a brand-change will occur: From 1 March, 2020:\textsuperscript{10}
- Riximyo will be funded for all new and existing patients requiring rituximab, except those with rheumatoid arthritis
- Riximyo will also be funded for the following new indications:
  - Maintenance treatment of CD20+ low-grade or follicular B-cell non-Hodgkin’s lymphoma
  - Graft versus host disease
  - Antisynthetase syndrome with lung disease
  - Anti-NMDA receptor encephalitis
  - Severe chronic inflammatory demyelinating neuropathy
  - Amending existing criteria for transplant indications to allow use for any organ
- MabThera will be funded for:
  - All new and existing patients with rheumatoid arthritis
  - Patients currently being treated with rituximab for all indications, other than the new indications above

From December 1, 2020:\textsuperscript{10}
- Riximyo will be funded for all indications, except rheumatoid arthritis, and will be the only funded brand of rituximab for these indications until 30 September, 2023
- MabThera will only be funded for patients with rheumatoid arthritis

Riximyo and MabThera are administered by intravenous infusion over several hours in a hospital setting because severe infusion reactions can occur.\textsuperscript{28, 30} Premedication with an analgesic/anti-pyretic and an antihistamine is given before each infusion.\textsuperscript{28, 30} Severe reactions generally occur within two hours of beginning the first infusion and may include pulmonary symptoms, fever, rigors, hypotension, urticaria and occasionally tumour lysis syndrome (with cancer treatment).\textsuperscript{28, 30}

The use of Riximyo and MabThera may be associated with progressive multifocal leukoencephalopathy and patients are monitored for the development of neurological symptoms.\textsuperscript{26, 30}

Comparability between Riximyo and MabThera was demonstrated by: \textsuperscript{31}

1. Establishing the structural and functional characteristics of Riximyo and MabThera with comprehensive binding and activity assays
2. Non-clinical testing, including pharmacokinetics, pharmacodynamics, toxicology and experiments with a mouse xenograft tumour model using a dose scaling design
3. Assessing effector mechanisms, specifically antibody dependent cellular cytotoxicity, complement-dependent cytotoxicity and apoptosis were assessed in whole blood assays from healthy volunteers
4. Two randomised clinical trials to confirm comparability; one in patients with rheumatoid arthritis (GP13-201) and another in patients with advanced follicular lymphoma (GP13-301)

The primary purpose of the clinical trial in patients with rheumatoid arthritis was to assess pharmacokinetics and pharmacodynamics and establish the bioequivalence of Riximyo, MabThera and Rituxan (rituximab licensed in the United States).\textsuperscript{31} The study enrolled 173 adult patients who had rheumatoid arthritis for at least six months and lasted for 52 weeks.\textsuperscript{31} The primary endpoint (equivalence of clinical response) was within the standard limits for bioequivalence and therefore consistent with biosimilarity, i.e. the ratio of the means for area under the curve (AUC) serum concentrations was 1.064 with a 90% confidence interval of 0.968, 1.169.\textsuperscript{31}

The purpose of the clinical trial in patients with follicular lymphoma was to compare the safety, efficacy,
Pharmacokinetics and pharmacodynamics of Riximyo and MabThera in patients with previously untreated, advanced stage follicular lymphoma. Patients (629) were given either Riximyo or MabThera in combination with cyclophosphamide, vincristine and prednisone for approximately six months, followed by maintenance treatment with Riximyo or MabThera for two years. Biosimilarity was concluded as the overall response rate was 87.1% in the Riximyo and 87.5% in the MabThera arm, with the 95% confidence interval for the difference between the two treatments being within the pre-specified equivalence.


Pharmacists should record the batch number when dispensing biological medicines

As biosimilars become available, it is best practice for pharmacists to query any prescription for a biological that refers to its generic rather than trade name. The batch number of the biological should also be recorded at dispensing to allow tracing of the medicine, if required.

Report suspected adverse reactions

Post-marketing surveillance of biological medicines is essential, especially when biosimilars are approved for indications where clinical trials have not been conducted.

If a patient has a suspected adverse reaction, an adverse reaction report should be completed, including the batch number of the biological medicine. Electronic reporting is recommended using the bestpractice adverse reaction reporting tool in your practice management system (for more information, see: [https://bpacsolutions.co.nz/products-national-consultation-suite/](https://bpacsolutions.co.nz/products-national-consultation-suite/)). Alternatively, an electronic form can be completed on the CARM website: [https://nzphvc.otago.ac.nz/reporting/](https://nzphvc.otago.ac.nz/reporting/), a report can be made via email (carmnz@otago.ac.nz) or using the pre-printed CARM adverse reaction card.

If a patient has responded poorly to a biosimilar and the reference medicine is no longer funded for that indication, a Named Patient Pharmaceutical Assessment application for
taking rituximab) found that 67% of patients who received a positively framed message were willing to switch to a biosimilar, compared to 46% of patients who had received a negatively framed message focusing on the differences between the biosimilar and the reference medicine.
funding may be necessary. Further information is available from: www.pharmac.govt.nz/tools-resources/forms/exceptional-circumstances/#npp

Further information on reporting adverse effects is available from:

Acknowledgement: Thank you to Dr Peter Ganly, Consultant Haematologist, Canterbury DHB and Clinical Senior Lecturer, Department of Pathology and Biomedical Science, University of Otago, Christchurch for expert review of this article.

Article supported by PHARMAC.

N.B. Expert reviewers do not write the articles and are not responsible for the final content. bpac™ retains editorial oversight of all content.

References


This article is available online at: www.bpac.org.nz/2020/biosimilars.asp